The purpose of this clinical trial is to study the effect of Narrow Band UVB on E-cadherin and integrin alpha v beta 1 as representatives of adhesion molecules in non-segmental vitiligo in a trial to verify a novel proposed mechanism of Narrow Band UVB. Additionally, specific melanocyte marker (Melan A) will be done to settle the localization of adhesion molecules in relation to melanocytes.

Inclusion Criteria:

• All clinically diagnosed cases of non-segmental vitiligo .
• Patients with VIDA +1 or more (new/expanding lesions active in time period of 6-12 months ago) will be included in the trial. Activity of vitiligo will be evaluated through Vitiligo Disease Activity (VIDA) Score.

Exclusion Criteria:

• Patients who have stable disease at the time of study i.e. no progression of existing disease or appearance of new lesions in the last six months.
• Patients receiving treatment for vitiligo 3 months prior to the study.
• Patients with contraindications for phototherapy.
• Patients with current/history of any systemic and/or dermatological diseases affecting the immune system as autoimmune diseases and malignancy.